menu
    • menu

    Find Omeprazole manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 26
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    Omeprazole

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 73590-58-6, Losec, Prilosec, Esomeprazole, Antra, Omeprazon
    Molecular Formula
    C17H19N3O3S
    Molecular Weight
    345.4  g/mol
    InChI Key
    SUBDBMMJDZJVOS-UHFFFAOYSA-N
    FDA UNII
    KG60484QX9
    Omeprazole
    A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
    Omeprazole is a Proton Pump Inhibitor. The mechanism of action of omeprazole is as a Proton Pump Inhibitor, and Cytochrome P450 2C19 Inhibitor.
    1 2D Structure

    Omeprazole

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
    2.1.2 InChI
    InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
    2.1.3 InChI Key
    SUBDBMMJDZJVOS-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
    2.2 Other Identifiers
    2.2.1 UNII
    KG60484QX9
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. H 168 68

    2. H 168-68

    3. H 16868

    4. Magnesium, Omeprazole

    5. Omeprazole Magnesium

    6. Omeprazole Sodium

    7. Prilosec

    8. Sodium, Omeprazole

    2.3.2 Depositor-Supplied Synonyms

    1. 73590-58-6

    2. Losec

    3. Prilosec

    4. Esomeprazole

    5. Antra

    6. Omeprazon

    7. Audazol

    8. Omapren

    9. Omepral

    10. Parizac

    11. Zegerid

    12. Mopral

    13. Miol

    14. Belmazol

    15. Ceprandal

    16. Dizprazol

    17. Dudencer

    18. Emeproton

    19. Epirazole

    20. Gastrimut

    21. Gastroloc

    22. Gibancer

    23. Indurgan

    24. Inhibitron

    25. Inhipump

    26. Logastric

    27. Pepticum

    28. Peptilcer

    29. Prazidec

    30. Sanamidol

    31. Secrepina

    32. Ulcometion

    33. Mepral

    34. Miracid

    35. Omeprol

    36. Omezol

    37. Omisec

    38. Omizac

    39. Ompanyt

    40. Ozoken

    41. Prysma

    42. Ramezol

    43. Ulceral

    44. Ulcesep

    45. Ulcozol

    46. Zefxon

    47. Zoltum

    48. Desec

    49. Elgam

    50. Lomac

    51. Ulsen

    52. Ultop

    53. Zimor

    54. Ocid

    55. Omed

    56. Omid

    57. Omep

    58. Demeprazol

    59. Nopramin

    60. Omeprazol

    61. Omezolan

    62. Paprazol

    63. Pepticus

    64. Prazentol

    65. Prazolit

    66. Procelac

    67. Regulacid

    68. Danlox

    69. Erbolin

    70. Lensor

    71. Morecon

    72. Nilsec

    73. Olexin

    74. Omegast

    75. Omesek

    76. Ortanol

    77. Osiren

    78. Proclor

    79. Result

    80. Ulcsep

    81. Victrix

    82. Zepral

    83. Exter

    84. Gasec

    85. Ulzol

    86. Omebeta 20

    87. Tedec Ulceral

    88. Aulcer

    89. Antra Mups

    90. Omerprazole

    91. Omez

    92. 119141-88-7

    93. Omepradex

    94. Omeprazolum

    95. H 168/68

    96. Gastrogard

    97. Nuclosina

    98. Omesec

    99. Omeprazole-d3

    100. Mfcd00083192

    101. Prestwick_808

    102. 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole

    103. 6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole

    104. H-168/68

    105. Omz

    106. Chebi:77260

    107. 119141-89-8

    108. 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole

    109. 1h-benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-

    110. Aisi'aomeilazuona Esomeprazole Sodium

    111. Nsc-751450

    112. Nsc-759192

    113. Chembl1503

    114. Nexiam

    115. Esomeprazole Sodium Salt

    116. 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1h-1,3-benzodiazole

    117. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole

    118. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1h-benzimidazole

    119. Mls000069373

    120. Kg60484qx9

    121. 73590-58-6 (free Form)

    122. Omeprazol [inn-spanish]

    123. Omeprazolum [inn-latin]

    124. Ncgc00016925-06

    125. Esomperazole

    126. Smr000058847

    127. Emilok

    128. Cas-73590-58-6

    129. Dsstox_cid_1080

    130. 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1h-benzimidazole

    131. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1h-1,3-benzodiazole

    132. Dsstox_rid_75929

    133. Dsstox_gsid_21080

    134. ( -)-omeprazole

    135. (r)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole

    136. Omeprazone

    137. Omeprazen

    138. Omeprazole Delayed-release

    139. Omeprazole Pellets

    140. 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole

    141. 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole

    142. 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1h-benzimidazole

    143. 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3h-benzoimidazole

    144. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole

    145. Prilosec (tn)

    146. (+-)-omeprazole

    147. Ccris 7099

    148. Hsdb 3575

    149. Sr-01000003003

    150. Unii-kg60484qx9

    151. Omeprazole-d6

    152. Omeprazole, Solid

    153. 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole

    154. Agi-010

    155. Omeprazole,(s)

    156. Omeprazole Solution

    157. Omeprazole-[d3]

    158. (rs)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) Methylsulfinyl)-1h-benzo(d)imidazole

    159. (rs)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) Methylsulfinyl)-1h-benzo[d]imidazole

    160. 326602-80-6

    161. Omeprazole S-isomer

    162. 2-(((3,5-dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1h-benzimidazole

    163. Omeprazole - Bio-x

    164. Dm-3458

    165. Omeprazole [usan:usp:inn:ban:jan]

    166. Omeprazole-13c,d3

    167. Omeprazole (prilosec)

    168. Omeprazole [mi]

    169. Omeprazole [inn]

    170. Omeprazole [jan]

    171. Maybridge4_002645

    172. Opera_id_1863

    173. Prestwick0_000493

    174. Prestwick1_000493

    175. Prestwick2_000493

    176. Prestwick3_000493

    177. (.+/-.)-omeprazole

    178. Omeprazole [hsdb]

    179. Omeprazole [usan]

    180. O0359

    181. Omeprazole [vandf]

    182. Upcmld-dp075

    183. Cid_4594

    184. Omeprazole [mart.]

    185. Schembl1191

    186. Omeprazole [usp-rs]

    187. Omeprazole [who-dd]

    188. H 16868

    189. Bspbio_000385

    190. Mls001076112

    191. Mls001424148

    192. Mls006010400

    193. Mls006011759

    194. Bidd:gt0189

    195. Spbio_002306

    196. Bpbio1_000425

    197. Gtpl4279

    198. Omeprazole (jp17/usp/inn)

    199. Omeprazole [green Book]

    200. Dtxsid6021080

    201. Omeprazole [orange Book]

    202. Schembl11995456

    203. Upcmld-dp075:001

    204. Chebi:91766

    205. Omeprazole [usp Impurity]

    206. Hms1528i05

    207. Hms1569d07

    208. Hms2052g17

    209. Hms2090e16

    210. Hms2090f11

    211. Hms2096d07

    212. Hms2232b21

    213. Hms3269d17

    214. Hms3394g17

    215. Hms3413j07

    216. Hms3651a11

    217. Hms3677j07

    218. Hms3713d07

    219. Omeprazole [usp Monograph]

    220. Pharmakon1600-01505693

    221. Zegerid Component Omeprazole

    222. Amy30573

    223. Bcp05852

    224. Bcp13592

    225. Bcp21299

    226. Hy-b0113

    227. Yosprala Component Omeprazole

    228. 2,3,5-trimethylpyridine/omeprazole

    229. Tox21_110686

    230. Tox21_200509

    231. Ac-401

    232. Bbl028172

    233. Bdbm50103597

    234. Bdbm50241343

    235. Dl-462

    236. Mfcd23135254

    237. Nsc751450

    238. Nsc759192

    239. S1389

    240. Stk623746

    241. Akos005066653

    242. Akos015895343

    243. Omeprazole Component Of Zegerid

    244. Tox21_110686_1

    245. Ac-4676

    246. Ccg-101130

    247. Ccg-213517

    248. Cs-1868

    249. Db00338

    250. Hs-0055

    251. Nc00380

    252. Nsc 751450

    253. Nsc 759192

    254. Omeprazole Component Of Yosprala

    255. (s)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3h-benzoimidazole

    256. Idi1_032523

    257. Ncgc00016925-01

    258. Ncgc00016925-02

    259. Ncgc00016925-03

    260. Ncgc00016925-04

    261. Ncgc00016925-05

    262. Ncgc00016925-07

    263. Ncgc00016925-08

    264. Ncgc00016925-10

    265. Ncgc00016925-11

    266. Ncgc00021522-03

    267. Ncgc00021522-04

    268. Ncgc00021522-05

    269. Ncgc00258063-01

    270. Omeprazole, Analytical Reference Material

    271. Bo164173

    272. Sy009746

    273. Sy077145

    274. Sbi-0206896.p001

    275. Ft-0601585

    276. Ft-0652860

    277. Ft-0653294

    278. Ft-0673283

    279. Ft-0689771

    280. H 199

    281. Sw196942-4

    282. A19447

    283. C07324

    284. D00455

    285. 141o887

    286. A837865

    287. A892647

    288. A937349

    289. Q422210

    290. Sr-01000003003-4

    291. Sr-01000003003-7

    292. Sr-01000003003-8

    293. 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)

    294. Brd-a55962179-001-04-9

    295. Brd-a55962179-001-08-0

    296. Brd-a55962179-001-20-5

    297. Brd-a88691025-001-07-4

    298. F0001-2386

    299. Z1672902589

    300. Omeprazole, British Pharmacopoeia (bp) Reference Standard

    301. Omeprazole, European Pharmacopoeia (ep) Reference Standard

    302. Omeprazole, United States Pharmacopeia (usp) Reference Standard

    303. 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1h-benzo[d]imidazole

    304. 5-methoxy-2-((s)-((4-methoxy-3,5-dimethyl-2- Pyridinyl)methyl)sulfinyl)-

    305. Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material

    306. (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole

    307. (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole

    308. (rs)-5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl)benzimidazole

    309. 1h-benzimidazole,5-methoxy-2-[(r)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-

    310. 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyrdinyl)-methyl]sulfinyl]-1h-benzimidazole

    311. 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole

    312. 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole

    313. 5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1h-benzo[d]imidazole

    314. 5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole

    315. 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- 1h-benzimidazole

    316. 5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1h-benzimidazole

    317. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-1h-benzimidazole

    318. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-benzimidazole

    319. 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]1h-benzimidazole

    320. 6-methoxy-2-(((4-methoxy-3,5-dimethyl Pyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole

    321. 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole

    322. 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1h-benzimidazole

    323. 6-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1h-benzimidazole

    324. 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole

    325. 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole

    326. 6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole

    327. 6-methoxy-2-[[(4-methoxy3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole

    328. 6-methoxy-2-[[(4methoxy-3,5-dimethyl2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole

    329. Omeprazole For Peak Identification, European Pharmacopoeia (ep) Reference Standard

    330. Omeprazole Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

    331. (omeprazole)5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole

    332. 1h-benzimidazole,6-methoxy-2-[(r)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-

    333. 5-methoxy-2-(((4-methoxy-3,5,-dimethyl-2-pyridinyl)-methyl)sulphinyl)-1h-benzimidazole

    334. 5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole (omeprazole)

    335. 5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole(omeprazole)

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 345.4 g/mol
    Molecular Formula C17H19N3O3S
    XLogP32.2
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count5
    Exact Mass345.11471265 g/mol
    Monoisotopic Mass345.11471265 g/mol
    Topological Polar Surface Area96.3 Ų
    Heavy Atom Count24
    Formal Charge0
    Complexity453
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 14  
    Drug NameNexium
    PubMed HealthEsomeprazole
    Drug ClassesGastric Acid Secretion Inhibitor, Gastrointestinal Agent
    Active IngredientEsomeprazole magnesium
    Dosage FormCapsule, delayed rel pellets; For suspension, delayed release
    RouteOral
    Strengtheq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet
    Market StatusPrescription
    CompanyAstrazeneca

    2 of 14  
    Drug NameNexium iv
    PubMed HealthOmeprazole (By mouth)
    Drug ClassesGastric Acid Secretion Inhibitor
    Drug LabelThe active ingredient in Omeprazole Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formul...
    Active IngredientEsomeprazole sodium
    Dosage FormInjectable
    RouteIntravenous
    Strengtheq 20mg base/vial; eq 40mg base/vial
    Market StatusPrescription
    CompanyAstrazeneca

    3 of 14  
    Drug NameOmeprazole
    PubMed HealthOmeprazole (By mouth)
    Drug ClassesGastric Acid Secretion Inhibitor
    Drug Label11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret...
    Active IngredientOmeprazole
    Dosage FormCapsule, delayed rel pellets; Tablet, delayed release
    Routeoral; Oral
    Strength10mg; 40mg; 20mg
    Market StatusTentative Approval; Over the Counter; Prescription
    CompanyActavis Labs Fl; Apotex; Sandoz; Kremers Urban Pharms; Zydus Pharms Usa; Dr Reddys Labs; Dexcel Pharma; Mylan; Impax Labs

    4 of 14  
    Drug NameOmeprazole magnesium
    PubMed HealthOmeprazole/Sodium Bicarbonate (By mouth)
    Drug ClassesGastric Acid Secretion Inhibitor
    Drug Label11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret...
    Active IngredientOmeprazole magnesium
    Dosage FormCapsule, delayed release
    RouteOral
    Strengtheq 20mg base
    Market StatusOver the Counter
    CompanyDr Reddys Labs

    5 of 14  
    Drug NamePrilosec
    Active IngredientOmeprazole magnesium; Omeprazole
    Dosage FormCapsule, delayed rel pellets; For suspension, delayed release
    RouteOral
    Strengtheq 10mg base/packet; 10mg; 40mg; 20mg; eq 2.5mg base/packet
    Market StatusPrescription
    CompanyAstrazeneca

    6 of 14  
    Drug NamePrilosec otc
    Active IngredientOmeprazole magnesium
    Dosage FormTablet, delayed release
    RouteOral
    Strengtheq 20mg base
    Market StatusOver the Counter
    CompanyAstrazeneca

    7 of 14  
    Drug NameZegerid
    Active Ingredientsodium bicarbonate; Omeprazole
    Dosage FormCapsule; For suspension
    RouteOral
    Strength20mg/packet; 1.1gm; 40mg/packet; 1.68gm/packet; 40mg; 20mg
    Market StatusPrescription
    CompanySantarus

    8 of 14  
    Drug NameNexium
    PubMed HealthEsomeprazole
    Drug ClassesGastric Acid Secretion Inhibitor, Gastrointestinal Agent
    Active IngredientEsomeprazole magnesium
    Dosage FormCapsule, delayed rel pellets; For suspension, delayed release
    RouteOral
    Strengtheq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet
    Market StatusPrescription
    CompanyAstrazeneca

    9 of 14  
    Drug NameNexium iv
    PubMed HealthOmeprazole (By mouth)
    Drug ClassesGastric Acid Secretion Inhibitor
    Drug LabelThe active ingredient in Omeprazole Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formul...
    Active IngredientEsomeprazole sodium
    Dosage FormInjectable
    RouteIntravenous
    Strengtheq 20mg base/vial; eq 40mg base/vial
    Market StatusPrescription
    CompanyAstrazeneca

    10 of 14  
    Drug NameOmeprazole
    PubMed HealthOmeprazole (By mouth)
    Drug ClassesGastric Acid Secretion Inhibitor
    Drug Label11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret...
    Active IngredientOmeprazole
    Dosage FormCapsule, delayed rel pellets; Tablet, delayed release
    Routeoral; Oral
    Strength10mg; 40mg; 20mg
    Market StatusTentative Approval; Over the Counter; Prescription
    CompanyActavis Labs Fl; Apotex; Sandoz; Kremers Urban Pharms; Zydus Pharms Usa; Dr Reddys Labs; Dexcel Pharma; Mylan; Impax Labs

    11 of 14  
    Drug NameOmeprazole magnesium
    PubMed HealthOmeprazole/Sodium Bicarbonate (By mouth)
    Drug ClassesGastric Acid Secretion Inhibitor
    Drug Label11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret...
    Active IngredientOmeprazole magnesium
    Dosage FormCapsule, delayed release
    RouteOral
    Strengtheq 20mg base
    Market StatusOver the Counter
    CompanyDr Reddys Labs

    12 of 14  
    Drug NamePrilosec
    Active IngredientOmeprazole magnesium; Omeprazole
    Dosage FormCapsule, delayed rel pellets; For suspension, delayed release
    RouteOral
    Strengtheq 10mg base/packet; 10mg; 40mg; 20mg; eq 2.5mg base/packet
    Market StatusPrescription
    CompanyAstrazeneca

    13 of 14  
    Drug NamePrilosec otc
    Active IngredientOmeprazole magnesium
    Dosage FormTablet, delayed release
    RouteOral
    Strengtheq 20mg base
    Market StatusOver the Counter
    CompanyAstrazeneca

    14 of 14  
    Drug NameZegerid
    Active Ingredientsodium bicarbonate; Omeprazole
    Dosage FormCapsule; For suspension
    RouteOral
    Strength20mg/packet; 1.1gm; 40mg/packet; 1.68gm/packet; 40mg; 20mg
    Market StatusPrescription
    CompanySantarus

    4.2 Therapeutic Uses

    Anti-Ulcer Agents; Enzyme Inhibitors

    National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)

    Omeprazole is indicated for the treatment of a complex of symptoms which may be caused by any of the conditions where a reduction of gastric acid secretion is required (e.g., duodenal ulcer, gastric ulcer, nonsteroidal anti-inflammatory drugs associated gastric and duodenal ulcer, reflux esophagitis, gastroesophageal reflex disease) or when no identifiable organic cause is found (i.e., functional dyspepsia). /Included in US product labeling/

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2131

    Omeprazole is indicated for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease. Omeprazole is indicated for the short-term treatment of erosive esophagitis (associated with gastroesophageal reflux disease) that has been diagnosed by endoscopy. Omeprazole also is indicated to maintain healing of erosive esophagitis. /Included in US product labeling/

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2131

    Omeprazole is indicated for the long-term treatment of pathologic gastric hypersecretion associated with Zollinger-Ellison syndrome (alone or as part of multiple endocrine neoplasia Type-1), systemic mastocytosis, and multiple endocrine adenoma. /Included in US product labeling/

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2131

    For more Therapeutic Uses (Complete) data for OMEPRAZOLE (8 total), please visit the HSDB record page.

    4.3 Drug Warning

    Pregnancy risk category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132

    No information is available on the relationship of age to the effects of omeprazole in geriatric patients. However, a somewhat decreased rate of elimination and increased bioavailability are more likely to occur in geriatric patients taking omeprazole.

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132

    Omeprazole generally is well tolerated. The most frequent adverse effects associated with omeprazole therapy involve the GI tract (e.g., diarrhea, nausea, constipation, abdominal pain, vomiting) and the CNS (e.g., headache, dizziness).

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 2839

    Diarrhea, abdominal pain, nausea, vomiting, constipation, flatulence, and acid regurgitation are the most frequent adverse GI effects of omeprazole, occurring in about 1-5% of patients. Dysphagia, abdominal swelling, anorexia, irritable colon, fecal discoloration, pancreatitis (sometimes fatal), esophageal candidiasis, mucosal atrophy of the tongue, taste perversion, and dry mouth have been reported occasionally but in many cases were not directly attributed to the drug. Benign gastric fundic polyps have been reported rarely and appear to resolve upon discontinuation of omeprazole therapy.

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 2840

    For more Drug Warnings (Complete) data for OMEPRAZOLE (15 total), please visit the HSDB record page.

    4.4 Drug Indication

    Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes: Treatment of active duodenal ulcer in adults Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults Treatment of active benign gastric ulcer in adults Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older Pathologic hypersecretory conditions in adults

    FDA Label

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    **Effects on gastric acid secretion** This drug decreases gastric acid secretion. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. **Effects on serum gastrin** In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors. **Enterochromaffin-like (ECL) cell effects** Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions. **Other effects** Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.

    5.2 MeSH Pharmacological Classification

    Anti-Ulcer Agents

    Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)

    Proton Pump Inhibitors

    Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    OMEPRAZOLE
    5.3.2 FDA UNII
    KG60484QX9
    5.3.3 Pharmacological Classes
    Cytochrome P450 2C19 Inhibitors [MoA]; Proton Pump Inhibitor [EPC]; Proton Pump Inhibitors [MoA]; Alkalinizing Activity [MoA]; Cytochrome P450 2C19 Inhibitors [MoA]
    5.4 ATC Code

    A02BC01

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    A - Alimentary tract and metabolism

    A02 - Drugs for acid related disorders

    A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

    A02BC - Proton pump inhibitors

    A02BC01 - Omeprazole

    A - Alimentary tract and metabolism

    A02 - Drugs for acid related disorders

    A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

    A02BC - Proton pump inhibitors

    A02BC05 - Esomeprazole

    5.5 Absorption, Distribution and Excretion

    Absorption

    Omeprazole delayed-release capsules contain an enteric-coated granule formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the granules exit the stomach. Absorption of omeprazole occurs rapidly, with peak plasma concentrations of omeprazole achieved within 0.5-3.5 hours. Absolute bioavailability (compared with intravenous administration) is approximately 30-40% at doses of 20-40 mg, largely due to pre-systemic metabolism. The bioavailability of omeprazole increases slightly upon repeated administration of omeprazole delayed-release capsules.

    Route of Elimination

    After a single dose oral dose of a buffered solution of omeprazole, negligible (if any) amounts of unchanged drug were excreted in urine. Most of the dose (about 77%) was eliminated in urine as at least six different metabolites. Two metabolites were identified as _hydroxyomeprazole_ and the corresponding _carboxylic acid_. The remainder of the dose was found in the feces. This suggests significant biliary excretion of omeprazole metabolites. Three metabolites have been identified in the plasma, the _sulfide_ and _sulfone_ derivatives of omeprazole, and _hydroxyomeprazole_. These metabolites possess minimal or no antisecretory activity.

    Volume of Distribution

    Approximately 0.3 L/kg, corresponding to the volume of extracellular water.

    Clearance

    Healthy subject (delayed release capsule), total body clearance 500 - 600 mL/min Geriatric plasma clearance: 250 mL/min Hepatic impairment plasma clearance: 70 mL/min

    Absorption: rapid. Distribution: Distributed in tissue, particularly gastric parietal cells.

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132

    Elimination: Renal 72 to 80%. Fecal 18 to 23%. In dialysis - Not readily dialyzable, because of extensive protein binding.

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132

    To clarify the in vivo first-pass metabolism of omeprazole, the pharmacokinetics were examined after oral, intraduodenal, intraportal venous, and intravenous administration at various doses to rats. Extraction ratios in the liver and intestinal tract were determined from the areas under the concentration-time curve (AUC) for intraportal venous and intravenous administration and from those for intraduodenal and intraportal venous administration, respectively. Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively. The bioavailability of orally administered omeprazole was 6.4, 9.6, and 12.6% at the doses of l0, 20, and 40 mg/kg, respectively. There were no differences in the distribution volume of steady state, total clearance, or elimination half-life at any doses. In addition, the AUC value after oral administration (20 mg/kg) in rats acutely intoxicated with CC(14) was 2.4 times larger than that in the control. These findings suggest that omeprazole undergoes a first-pass metabolism in the intestinal mucosa and/or lumen, as well as in the liver, and that the major contribution to the dose-dependent increase in bioavailability is a saturation of the first-pass metabolism in the liver.

    PMID:7983597 Watanabe K et al; J Pharm Sci 83 (8): 1131-4 (1994)

    Omeprazole is distributed into human milk; following oral administration of omeprazole 20 mg in one lactating women, concentrations of the drug were measured in breast milk.

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 2841

    For more Absorption, Distribution and Excretion (Complete) data for OMEPRAZOLE (6 total), please visit the HSDB record page.

    5.6 Metabolism/Metabolites

    Omeprazole is heavily metabolized in the liver by the cytochrome P450 (CYP) enzyme system. The main part of its metabolism depends on the polymorphically expressed CYP2C19, which is responsible for the formation of _hydroxyomeprazole_, the major metabolite found in plasma. The remaining part depends on CYP3A4, responsible for the formation of _omeprazole sulphone_.

    The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the major omeprazole metabolites. 2 The four major metabolites identified in vitro, in tentative order of importance, were hydroxyomeprazole, omeprazole sulphone, 5-O-desmethylomeprazole, and an unidentified compound termed metabolite X. Omeprazole pyridone was also detected but could not be quantitated. Incubation of hydroxyomeprazole and omeprazole sulphone with human microsomes resulted in both cases in formation of the hydroxysulphone. The kinetics of formation of the four primary metabolites studied were biphasic suggesting the involvement of multiple CYP isoforms in each case. Further studies used substrate concentrations at which the high affinity activities predominated. 3 Formation of the major metabolite, hydroxyomeprazole, was significantly correlated with S-mephenytoin hydroxylase and with benzo[a]pyrene metabolism and CYP3A content. Inhibition studies with isoform selective inhibitors also indicated a dominant role of S-mephenytoin hydroxylase with some CYP3A contribution in the formation of hydroxyomeprazole. Correlation and inhibition data for the sulphone and metabolite X were consistent with a predominant role of the CYP3A subfamily in formation of these metabolites. Formation of 5-O-desmethylomeprazole was inhibited by both R, S-mephenytoin and quinidine, indicating that both S-mephenytoin hydroxylase and CYP2D6 may mediate this reaction in human liver microsomes and in vivo. The Vmax/Km (indicator of intrinsic clearance in vivo) for hydroxyomeprazole was four times greater than that for omeprazole sulphone. Consistent with findings in vivo, the results predict that omeprazole clearance in vivo would be reduced in poor metabolisers of mephenytoin due to reduction in the dominant partial metabolic clearance to hydroxyomeprazole.

    PMID:12959268 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364656 Andersson T et al; Br J Clin Pharmacol 36 (6): 521-30 (1993)

    Omeprazole has known human metabolites that include 3-Hydroxyomeprazole, 5'-O-Desmethyl omeprazole, 5-Hydroxyomeprazole, and Omeprazole sulfone.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.7 Biological Half-Life

    0.5-1 hour (healthy subjects, delayed-release capsule) Approximately 3 hours (hepatic impairment)

    Plasma - Normal hepatic function - 30 minutes to 1 hour. Chronic hepatic disease - 3 hours.

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132

    5.8 Mechanism of Action

    Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump, expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid). Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours. This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus. **Mechanism of H. pylori eradication** Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs). The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen,. _H. pylori_ replicates most effectively at a neutral pH. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions.

    Omeprazole is a selective and irreversible proton pump inhibitor. Omeprazole suppresses gastric acid secretion by specific inhibition of the hydrogen-potassium adenosinetriphosphatase (H+, K+-ATPase) enzyme system found at the secretory surface of parietal cells. It inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen. Since the H+/K+ ATPase enzyme system is regarded as the acid (proton) pump of the gastric mucosa, omeprazole is known as a gastric acid pump inhibitor. Omeprazole inhibits both basal and stimulated acid secretion irrespective of the stimulus.

    Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132

    After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H + /K + ATPase enzyme. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days.

    Physicians Desk Reference. 58th ed. Thomson PDR. Montvale, NJ 2004., p. 634

    API SUPPLIERS

    read-more
    read-more

    01

    Gonane Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    iPHEX India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Gonane Pharma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 14969

    Submission : 2000-07-31

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    Sanofi Company Banner

    03

    Metrochem API Private Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    MAGHREB Pharma Expo
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34759

    Submission : 2020-06-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2020-182 - Rev 01

    Issue Date : 2024-07-23

    Type : Chemical

    Substance Number : 942

    Status : Valid

     JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2024-04-03

    Valid Till : 2027-01-21

    Written Confirmation Number : WC-0493

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 42765-010

    Start Marketing Date : 2020-06-22

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Metrochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Rochem International Inc

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Rochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Sangjin Trading Co., Ltd.

    Registration Date : 2015-08-11

    Registration Number : 20150811-52-B-378-18

    Manufacturer Name : Dr. Reddy\'s Laboratories Limited(Unit V)_x000D_

    Manufacturer Address : Unit V, Peddadevulapalli, Tripuraram Mandal, Nalgonda District, Telangana State, India

     VMF ASMF arrow-down
    ✖
    Available Reg Filing : ASMF
    AUDIT arrow-down
    Dr Reddy Company Banner

    06

    Jai Radhe Sales

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Jai Radhe Sales

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Pharm-RX Chemical

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    SupplySide West
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPharm-Rx is a reputed global importer and distributor of pharmaceutical active ingredients.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Pharm RX

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Tenatra Exports

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Tenatra

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Zeon Pharma Industries India Pvt L...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothZeon Pharma is a manufacturer and supplier of APIs & Intermediates.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Zeon Pharma Industries India Pvt Ltd

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Granules India Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2023-08-08

    Pay. Date : 2023-07-17

    DMF Number : 37449

    Submission : 2022-09-29

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 62207-983

    Start Marketing Date : 2023-01-09

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (20kg/20kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF ASMF arrow-down
    ✖
    Available Reg Filing : ASMF
    AUDIT
    Granules India

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-moreread-more

    01

    Sanyo Fine Co Ltd

    France
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 14969

    Submission : 2000-07-31

    Status : Inactive

    Type : II

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Metrochem Api Private Ltd

    India
    arrow
    CPhI Japan
    Booth #1J-48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34759

    Submission : 2020-06-03

    Status : Active

    Type : II

    Metrochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Dr Reddys Laboratories Ltd

    India
    arrow
    MAGHREB Pharma Expo
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2013-03-15

    Pay. Date : 2013-03-01

    DMF Number : 12917

    Submission : 1998-03-25

    Status : Active

    Type : II

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dr Reddys Laboratories Ltd

    India
    arrow
    MAGHREB Pharma Expo
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2014-02-18

    Pay. Date : 2014-01-24

    DMF Number : 24640

    Submission : 2011-02-16

    Status : Active

    Type : II

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Dr Reddys Laboratories Ltd

    India
    arrow
    MAGHREB Pharma Expo
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 19713

    Submission : 2006-08-28

    Status : Active

    Type : II

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Granules India Ltd

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2023-08-08

    Pay. Date : 2023-07-17

    DMF Number : 37449

    Submission : 2022-09-29

    Status : Active

    Type : II

    Granules India

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Tapi Nl Bv

    Israel
    arrow
    CPhI Japan
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Contact Supplier Contact Supplier
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2013-08-08

    Pay. Date : 2012-11-09

    DMF Number : 25621

    Submission : 2011-12-22

    Status : Active

    Type : II

    TAPI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Astra Research Laboratories

    United Kingdom

    USDMF

    arrow
    AACR Annual meeting
    Not Confirmed

    08

    Astra Research Laboratories

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 4863

    Submission : 1983-03-31

    Status : Inactive

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Esteve Quimica Sa

    Spain

    USDMF

    arrow
    AACR Annual meeting
    Not Confirmed

    09

    Esteve Quimica Sa

    Spain
    arrow
    AACR Annual meeting
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 11794

    Submission : 1995-12-21

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Esteve Quimica Sa

    Spain

    USDMF

    arrow
    AACR Annual meeting
    Not Confirmed

    10

    Esteve Quimica Sa

    Spain
    arrow
    AACR Annual meeting
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 11017

    Submission : 1994-08-02

    Status : Inactive

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Gonane Pharma

    India
    arrow
    iPHEX India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Gonane Pharma is a contract pharmaceutical company based in Gujarat, India, specializing in the manufacturing and marketing of corticosteroids, hormones, antivirals, and oncology p...

    Gonane Pharma is a contract pharmaceutical company based in Gujarat, India, specializing in the manufacturing and marketing of corticosteroids, hormones, antivirals, and oncology products. The company is supported by a dedicated team and promoters with over 25 years of experience in manufacturing, product promotion, and regulatory audits across markets including the EU, Mexico, China, Korea, and Russia. Gonane Pharma is also engaged with Japanese customers and continues to expand into new markets. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Gonane Pharma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Metrochem API Private Limited

    India
    arrow
    CPhI Japan
    Booth #1J-48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

    Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
    Metrochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Rochem International Inc

    U.S.A
    arrow
    CPhI China
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Rochem, established in 1994, is a global distributor of pharmaceutical, food, nutritional, and animal health ingredients, sourcing high-quality products from China. Headquartered i...

    Rochem, established in 1994, is a global distributor of pharmaceutical, food, nutritional, and animal health ingredients, sourcing high-quality products from China. Headquartered in Hauppauge, New York, it operates 16 offices worldwide. Rochem’s operations are fully cGMP compliant and have been audited by the USFDA and several multinational organizations. The company also trains and audits its partners to ensure FDA-compliant technologies and systems. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Rochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dr. Reddy's Laboratories

    India
    arrow
    CPhI Japan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

    Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Jai Radhe Sales

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...

    Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and regulatory support, and strives for global standards. Known for quality and affordability, it has established a niche through innovative methods and exports to nearly every continent. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Jai Radhe Sales

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Pharm-RX Chemical

    U.S.A
    arrow
    SupplySide West
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPharm-Rx is a reputed global importer and distributor of pharmaceutical active ingredients.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Established in 1991, Pharm-Rx is an importer and distributor of active ingredients serving the pharmaceutical, nutritional supplement, and food industries. The company follows a hi...

    Established in 1991, Pharm-Rx is an importer and distributor of active ingredients serving the pharmaceutical, nutritional supplement, and food industries. The company follows a highly selective supplier qualification process, including direct visits to overseas manufacturers, to maintain high quality standards. Pharm-Rx’s growth is driven by a consistent focus on quality ingredients, competitive pricing, and customer service. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Pharm RX

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Tenatra Exports

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...

    Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opportunities grew, it was felt that the proprietorship firm had outlived its usefulness and that it needed a corporate structure. So, Tenatra Exports Private Limited was incorporated in 2002. Since then, the company has come a long way, gaining valuable experience and knowledge in the fields of chemicals and pharmaceuticals in India. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Tenatra

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Zeon Pharma Industries India Pvt Lt...

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothZeon Pharma is a manufacturer and supplier of APIs & Intermediates.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), phytochemicals, herba...

    Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), phytochemicals, herbal extracts, semi-finished granules, and finished formulations such as tablets, capsules, and dry suspensions. The company also provides product support through associate manufacturing plants for APIs, pellets, excipients, enzymes, and specialized chemicals, operating in compliance with cGMP, WHO-GMP, and EU-GMP standards. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Zeon Pharma Industries India Pvt Ltd

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Granules India Limited

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the ...

    Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the entire value chain- APIs, Formulation Intermediates, & Formulations. With 11 facilities (8 in India, 2 in the US and 1 in Europe) approved by US FDA, EDQM, EU GMP, WHO GMP, & more, its products reach 300+ customers in 80+ countries. Granules has offices in India, the US, & Europe ensuring a strong global presence. Products listed herein may not be available for commercial use in countries where any relevant third-party intellectual property is in force.
    Granules India

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    TAPI Technology & API Services

    Israel
    arrow
    CPhI Japan
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Contact Supplier Contact Supplier
    Flag Israel
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Omeprazole

    About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

    Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
    TAPI Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - ...DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19810

    read-more

    DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - ...DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19810

    read-more

    DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - ...DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 19810

    read-more

    DOSAGE - TABLET, DELAYED RELEASE;ORAL - 325MG...DOSAGE - TABLET, DELAYED RELEASE;ORAL - 325MG;40MG

    USFDA APPLICATION NUMBER - 205103

    read-more

    DOSAGE - TABLET, DELAYED RELEASE;ORAL - 81MG;...DOSAGE - TABLET, DELAYED RELEASE;ORAL - 81MG;40MG

    USFDA APPLICATION NUMBER - 205103

    read-more

    DOSAGE - TABLET, ORALLY DISINTEGRATING, DELAY...DOSAGE - TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL - 20MG

    USFDA APPLICATION NUMBER - 209400

    read-more

    DOSAGE - CAPSULE;ORAL - 20MG;1.1GM **Federal ...DOSAGE - CAPSULE;ORAL - 20MG;1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 21849

    read-more

    DOSAGE - CAPSULE;ORAL - 40MG;1.1GM **Federal ...DOSAGE - CAPSULE;ORAL - 40MG;1.1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 21849

    read-more

    DOSAGE - TABLET, DELAYED RELEASE;ORAL - 20MG

    USFDA APPLICATION NUMBER - 22032

    read-more

    DOSAGE - CAPSULE;ORAL - 20MG;1.1GM

    USFDA APPLICATION NUMBER - 22281

    read-more

    DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RE...DOSAGE - CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL - 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 50824

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Granulation

    read-more
    read-more

    01

    SPI Pharma

    U.S.A
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSPI Pharma has been solving formulation challenges using superior functional materials.

    Brand Name : Mannogem Powder

    Application : Fillers, Diluents & Binders, Granulation, Solubilizers

    Excipient Details : Mannogem (mannitol powder) is an excellent excipient for use in wet granulation, lyophilization & improves solubility of poorly soluble APIs.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Mannitol

    arrow
    Mannogem Powder

    Excipients Web Link

    Virtual Booth

    02

    SPI Pharma

    U.S.A
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSPI Pharma has been solving formulation challenges using superior functional materials.

    Dosage Form : Tablet

    Grade : Oral

    Category : Granulation

    Brand Name : Magnesium Hydroxide 5100

    Application : Granulation

    Excipient Details : Magnesium Hydroxide powder 5100 is used in wet granulation tableting applications for the production of antacid tablets and digestive aids.

    Pharmacopoeia Ref : USP, Ph. Eur.

    Technical Specs : Tapped Density: 0.68-0.84

    Ingredient(s) : Magnesium Hydroxide Excipient

    arrow
    Magnesium Hydroxide 5100

    Excipients Web Link

    Virtual Booth

    03

    SPI Pharma

    U.S.A
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSPI Pharma has been solving formulation challenges using superior functional materials.

    Dosage Form : Tablet

    Grade : Oral

    Category : Granulation

    Brand Name : Magnesium Hydroxide 5300

    Application : Granulation

    Excipient Details : Magnesium Hydroxide powder 5300 is used in wet granulation tableting applications for the production of antacid tablets and digestive aids.

    Pharmacopoeia Ref : USP, Ph. Eur.

    Technical Specs : Tapped Density: 0.60-0.90

    Ingredient(s) : Magnesium Hydroxide Excipient

    arrow
    Magnesium Hydroxide 5300

    Excipients Web Link

    Virtual Booth

    04

    Pluviaendo

    Turkey
    AACR Annual meeting
    Not Confirmed
    arrow

    05

    The Dow Chemical Company

    U.S.A
    AACR Annual meeting
    Not Confirmed
    arrow

    06

    Prachin Chemical

    India
    AACR Annual meeting
    Not Confirmed
    arrow

    07

    BASF

    Germany
    AACR Annual meeting
    Not Confirmed
    arrow

    08

    Ulanqab Kema New Material

    China
    AACR Annual meeting
    Not Confirmed
    arrow

    09

    Sigachi Industries

    India
    AACR Annual meeting
    Not Confirmed
    arrow

    10

    Novo Excipients

    India
    AACR Annual meeting
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Thickeners and Stabilizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Topical

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ANALYTICAL

    Upload your methods for free, ask us

    Analytical Methods

    read-more
    read-more

    ABOUT THIS PAGE

    Looking for 73590-58-6 / Omeprazole API manufacturers, exporters & distributors?

    Omeprazole manufacturers, exporters & distributors 1

    59

    PharmaCompass offers a list of Omeprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Omeprazole manufacturer or Omeprazole supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Omeprazole manufacturer or Omeprazole supplier.

    API | Excipient name

    Omeprazole

    Synonyms

    73590-58-6, Losec, Prilosec, Esomeprazole, Antra, Omeprazon

    Cas Number

    73590-58-6

    Unique Ingredient Identifier (UNII)

    KG60484QX9

    About Omeprazole

    A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

    Omebeta 20 Manufacturers

    A Omebeta 20 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Omebeta 20, including repackagers and relabelers. The FDA regulates Omebeta 20 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Omebeta 20 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Omebeta 20 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Omebeta 20 Suppliers

    A Omebeta 20 supplier is an individual or a company that provides Omebeta 20 active pharmaceutical ingredient (API) or Omebeta 20 finished formulations upon request. The Omebeta 20 suppliers may include Omebeta 20 API manufacturers, exporters, distributors and traders.

    click here to find a list of Omebeta 20 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Omebeta 20 USDMF

    A Omebeta 20 DMF (Drug Master File) is a document detailing the whole manufacturing process of Omebeta 20 active pharmaceutical ingredient (API) in detail. Different forms of Omebeta 20 DMFs exist exist since differing nations have different regulations, such as Omebeta 20 USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Omebeta 20 DMF submitted to regulatory agencies in the US is known as a USDMF. Omebeta 20 USDMF includes data on Omebeta 20's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Omebeta 20 USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Omebeta 20 suppliers with USDMF on PharmaCompass.

    Omebeta 20 JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Omebeta 20 Drug Master File in Japan (Omebeta 20 JDMF) empowers Omebeta 20 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Omebeta 20 JDMF during the approval evaluation for pharmaceutical products. At the time of Omebeta 20 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Omebeta 20 suppliers with JDMF on PharmaCompass.

    Omebeta 20 KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Omebeta 20 Drug Master File in Korea (Omebeta 20 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Omebeta 20. The MFDS reviews the Omebeta 20 KDMF as part of the drug registration process and uses the information provided in the Omebeta 20 KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Omebeta 20 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Omebeta 20 API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Omebeta 20 suppliers with KDMF on PharmaCompass.

    Omebeta 20 CEP

    A Omebeta 20 CEP of the European Pharmacopoeia monograph is often referred to as a Omebeta 20 Certificate of Suitability (COS). The purpose of a Omebeta 20 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Omebeta 20 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Omebeta 20 to their clients by showing that a Omebeta 20 CEP has been issued for it. The manufacturer submits a Omebeta 20 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Omebeta 20 CEP holder for the record. Additionally, the data presented in the Omebeta 20 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Omebeta 20 DMF.

    A Omebeta 20 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Omebeta 20 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Omebeta 20 suppliers with CEP (COS) on PharmaCompass.

    Omebeta 20 WC

    A Omebeta 20 written confirmation (Omebeta 20 WC) is an official document issued by a regulatory agency to a Omebeta 20 manufacturer, verifying that the manufacturing facility of a Omebeta 20 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Omebeta 20 APIs or Omebeta 20 finished pharmaceutical products to another nation, regulatory agencies frequently require a Omebeta 20 WC (written confirmation) as part of the regulatory process.

    click here to find a list of Omebeta 20 suppliers with Written Confirmation (WC) on PharmaCompass.

    Omebeta 20 NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Omebeta 20 as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Omebeta 20 API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Omebeta 20 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Omebeta 20 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Omebeta 20 NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Omebeta 20 suppliers with NDC on PharmaCompass.

    Omebeta 20 GMP

    Omebeta 20 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Omebeta 20 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Omebeta 20 GMP manufacturer or Omebeta 20 GMP API supplier for your needs.

    Omebeta 20 CoA

    A Omebeta 20 CoA (Certificate of Analysis) is a formal document that attests to Omebeta 20's compliance with Omebeta 20 specifications and serves as a tool for batch-level quality control.

    Omebeta 20 CoA mostly includes findings from lab analyses of a specific batch. For each Omebeta 20 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Omebeta 20 may be tested according to a variety of international standards, such as European Pharmacopoeia (Omebeta 20 EP), Omebeta 20 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Omebeta 20 USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search